Erectol is commonly used in Andrology and Male Sexual Medicine to treat erectile dysfunction. The medication provides supportive therapeutic benefit by addressing the core issue of difficulty achieving or maintaining a penile erection adequate for satisfactory sexual intercourse. It is applicable for men experiencing a range of severity, from mild to severe dysfunction, and is relevant in situations involving recurrent episodic failures.

The primary indication is to manage symptoms of male sexual dysfunction characterized by impaired penile rigidity and erection maintenance failure.

“The primary goal of use is to offer symptomatic relief and helps to support functional capacity.”

Supporting Functional Performance and Stability

The medication is applied in clinical settings when short-term symptomatic assistance is needed prior to sexual activity. The general patient-oriented benefit assists with maintaining functional stability, which in turn helps to ease the overall symptom burden, contributes to improved comfort, and supports a fuller, more manageable experience of successful sexual activity when sexually aroused. This makes it relevant for men with organic or psychogenic components to their condition.

---

Quick Fact: Relief for Impaired Penile Rigidity Erectol is commonly used to help manage the symptom cluster where functional capacity for erection is compromised, providing supportive relief for inadequate penile rigidity and the associated difficulty achieving an erection.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Erectol (Sildenafil)

This information describes official patient eligibility based strictly on regulatory documents, defining groups who must not use the medicine.

---

Contraindications (Must Not Use)

Erectol is officially contraindicated (prohibited) in patients with the following conditions or circumstances:

• Concomitant use of any form of organic nitrates (regularly or intermittently) due to the risk of life-threatening hypotension.
• Concomitant use of guanylate cyclase stimulators (e.g., riociguat).
• Known hypersensitivity to sildenafil or any component of the tablet.
• Severe hepatic impairment or severe hypotension (resting blood pressure less than 90/50 mmHg).
• Recent history of myocardial infarction or stroke (within the last six months).
• Loss of vision in one eye due to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).

Eligibility and Restricted Use

Population / Condition	Eligibility Status
Pediatric Use	Not Indicated (below 18 years of age)
Women	Not Indicated for this use.
Severe Cardiovascular Disease	Not Recommended if sexual activity is medically inadvisable (e.g., severe cardiac failure, unstable angina).
Predisposition to Priapism	Use with Caution (e.g., sickle cell anaemia, anatomical deformation of the penis).

Erectol is indicated only for use in adult men for the treatment of erectile dysfunction.

Interactions with other medicines and products

Erectol (Sildenafil) has officially documented interaction patterns primarily concerning its vasodilatory effects and its metabolic clearance via the CYP3A4 enzyme, as defined by regulatory prescribing information.

Contraindicated Combinations

The co-administration of Erectol with specific medications is strictly contraindicated due to the risk of severe drug-drug interactions.

• Organic Nitrates: Co-administration with any form of organic nitrate (e.g., nitroglycerin, isosorbide dinitrate) is prohibited. Sildenafil potentiates the hypotensive effects of nitrates, which can lead to a significant, life-threatening drop in blood pressure.
• Riociguat: Use with the soluble guanylate cyclase (sGC) stimulator Riociguat is prohibited, as PDE5 inhibitors may potentiate its hypotensive effects.

Pharmacokinetic and Pharmacodynamic Interactions

The drug's interaction profile is structured around metabolic and systemic effects:

• Strong CYP3A4 Inhibitors: Medications such as Ritonavir or Ketoconazole substantially inhibit the metabolism of Sildenafil, leading to increased systemic exposure. A regulatory restriction limits the maximum single dose of Sildenafil to 25 mg in a 48-hour period when used with Ritonavir.
• Alpha-Blockers: Co-administration with alpha-adrenergic blocking agents (e.g., Doxazosin) causes additive blood pressure-lowering effects (pharmacodynamic interaction). Regulatory guidance mandates a specific lower starting dose of Sildenafil when co-administered.
• Food/Supplements: Grapefruit juice may increase Sildenafil plasma levels by inhibiting metabolism, while the herbal product St. John’s Wort may decrease levels by inducing the CYP3A4 enzyme.

Conserving the cGMP Signaling Molecule

This mechanism is centered on the enzyme Phosphodiesterase type 5 ( PDE5), which normally hydrolyzes the crucial signaling molecule, cyclic GMP ( cGMP). The active ingredient acts as a selective inhibitor of PDE5, thereby conserving cGMP levels in smooth muscle cells. This core action conserves cGMP, which functions as the direct signal for vascular smooth muscle relaxation.

---

Amplification of the Natural NO Pathway

The drug's mechanism of action is strictly dependent on the Nitric Oxide ( NO)- cGMP pathway, which is initiated by physiological stimulation. The drug does not create cGMP or NO; instead, it modulates the natural signal by preventing cGMP from being rapidly metabolized. This amplification extends the duration and intensity of the molecular signal, promoting vasodilation in the targeted tissue.

---

Driving Systemic Physiological Changes

The resulting conservation of cGMP increases the signal for relaxation of arterial and trabecular smooth muscle, leading to significant dilation of blood vessels. This physiological change facilitates a substantial increase in localized blood inflow, which simultaneously compresses veins (veno-occlusion). This cascade of molecular ightarrow cellular ightarrow systemic events is the mechanism by which the drug promotes the physiological outcome of tissue engorgement.

How Erectol (Sildenafil) is Used

The administration of Erectol, which contains the active ingredient sildenafil, follows an as-needed, episodic use pattern. The medication is available as film-coated tablets for oral administration only.

Standard Dosing and Timing

For most patients, the typical starting dose is 50 mg taken approximately one hour before sexual activity. However, the medication can be taken anywhere from 30 minutes to 4 hours prior to activity. Based on individual response, the dose may range from a minimum of 25 mg to a maximum single dose of 100 mg. The maximum recommended dosing frequency for the oral tablet is strictly once per day.

Administration is generally independent of meals, as the tablets can be taken with or without food. Ingestion of the tablet with a high-fat meal may lead to a delay in the onset of its activity.

Population-Specific Administration Rules

A starting dose of 25 mg applies to certain patient groups, including older adults (65 years of age or older), patients with severe renal impairment (creatinine clearance < 30 mL/min), and those with hepatic impairment (e.g., cirrhosis). Furthermore, specific dose parameters apply when certain other medications are co-administered; for instance, the maximum dose is 25 mg within a 48-hour period when taken concurrently with ritonavir. The tablets are not indicated for use by individuals under 18 years of age.

Research Evidence: Overview of Studies for Erectol

This section provides a factual summary of the research evidence for the active ingredient in Erectol (Sildenafil), detailing the types of studies conducted and the specific outcomes they were designed to measure. Findings describe group patterns and are not personal predictions.

---

Evidence for Use in Erectile Dysfunction (ED)

The core evidence was studied in numerous randomized controlled trials (RCTs). These studies were generally short-term, lasting a few weeks, and applied in research contexts involving fluctuating or unstable symptoms by comparing the study drug against an inactive placebo. The populations included adult males spanning a broad range of ages and various origins of the condition.

Researchers examined outcomes reflecting daily functioning or activity level using standardized patient-reported scales, such as the International Index of Erectile Function (IIEF). They also monitored the percentage of successful attempts at sexual intercourse as patient-reported outcomes describing perceived discomfort. In these short-term trials, findings describe patterns observed in the studies related to measured scores on these functional scales, and the research is part of the available scientific record regarding the condition.

---

Evidence in Specific Patient Subgroups

Research was evaluated in specific patient groups where the condition is a condition marked by functional limitations due to underlying health issues. Studies explored short-term symptom changes in men with ED associated with conditions such as diabetes mellitus and hypertension. Trials also examined outcomes in men following certain surgeries, such as nerve-sparing radical prostatectomy.

In these specific patient populations, the research describes changes measured during the study period. However, for certain surgical subgroups, such as those who underwent non-nerve-sparing procedures, data were heterogeneous, and the research is not sufficient to draw specific conclusions for these more complex cases.

---

Research Gaps and What Remains Uncertain

Despite the breadth of the research, several areas remain uncertain or less studied. Comparative evidence is lacking—few studies were observed in research directly comparing Erectol’s active ingredient against other currently available active treatments. Additionally, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the durability of these patterns over many years. The available data are still emerging, and the research does not determine whether an individual will respond similarly to the group findings.

Key Studies & References

1. Sildenafil - StatPearls - NCBI Bookshelf (Used for regulatory and general indication context)

Common questions about Erectol (FAQ)

Q: How long after taking Erectol should a person expect it to start working?

Regulatory documents describe the time it takes for the medicine to reach its peak level in the body. According to the official product information, maximum concentration in the blood may be observed between 30 minutes and 2 hours after the tablet is taken in research studies involving fasted participants.

---

Q: How long does the effect of a single dose of Erectol typically last?

The length of time the active ingredient remains in the system is described in official documents as part of its pharmacological properties. The drug and its major active breakdown product have a terminal elimination half-life of approximately 4 hours. This time frame indicates the period required for half of the drug to be processed and cleared from the body.

---

Q: Is Erectol known to cause any long-term health problems?

Official documentation provides a description of the known safety profile and adverse reactions identified in clinical trials and during ongoing post-marketing surveillance. The available research evidence indicates that long-term effects related to the durability and safety of chronic treatment patterns are not fully established.

---

Q: Can women or children ever take Erectol for any reason?

The specific formulation of Erectol for treating erectile dysfunction is not indicated for use by women or individuals under 18 years of age. However, the same active ingredient is also contained in a different prescription drug formulation that is indicated for treating Pulmonary Arterial Hypertension (PAH) in various patient populations.

---

Q: Is it possible for Erectol to affect laboratory test results?

Official drug labels do not generally contain information listing specific interference with common diagnostic laboratory tests. However, regulatory post-marketing studies and surveillance programs often monitor laboratory values as part of the continuous assessment of the drug’s overall safety profile in the general patient population.

---

Q: Why do people sometimes misunderstand how Erectol is supposed to be used?

Official information explains that research confirms that the drug requires a specific physiological trigger to produce an effect. Misunderstandings may stem from an expectation that the medicine will create an effect without the necessary physiological stimulus.

---

Q: What happens in the body when Erectol is starting to wear off?

As the drug wears off, the active ingredient is processed and cleared from the body. This process is primarily handled by the liver (hepatic metabolism). The breakdown products (metabolites) are then mostly eliminated in the feces, and to a lesser extent, in the urine.

---

Q: Does Erectol only work in certain specific situations?

Yes, regulatory documentation makes it clear that the drug is only observed to produce an effect when physiological stimulation is present.

---

Q: Is there a maximum number of times Erectol can be used per week?

Regulatory information addresses the maximum frequency for administration, stating that the maximum recommended dosing frequency is once per day. There is no official regulatory instruction that limits the frequency to less than one dose per day.

---

Q: How is Erectol different from a placebo in clinical trials?

Clinical trials systematically compared measured outcomes between the drug and an inactive placebo. During research, researchers monitored safety outcomes and observed that the rate of certain serious cardiovascular events in patients taking the study drug was comparable to placebo.

---

Q: Are there generic versions of Erectol available?

Erectol is the brand name for the active ingredient, Sildenafil. Once a drug's patent expires, other manufacturers are able to produce and market the same active ingredient, Sildenafil, under different generic names.

---

Q: What kind of studies support the use of Erectol?

The use of the drug is supported by findings from randomized, placebo-controlled clinical trials. These studies focused on adult males and examined specific measured outcomes related to the condition the drug is indicated for.

---

Q: Is Erectol safe for people who have had a stroke?

Regulatory warnings indicate that the drug should not be used in patients who have experienced a myocardial infarction (heart attack) or stroke within the last six months. This restriction reflects caution documented in the regulatory information for patients with a very recent history of severe cardiovascular events.

---

Q: Does the time of day matter when taking Erectol?

Product information specifies the timing of administration in relation to sexual activity. Additionally, taking the dose with a high-fat meal may cause a delay in the onset of effect. It is not restricted to a specific time of day like morning or evening.

---

Q: How does the official documentation describe the success rate of Erectol?

Clinical analyses summarizing research results indicate patterns observed in studies. One analysis of study findings reported a measured improvement in outcomes for approximately 77% of participants across various patient groups. This describes group findings in the research context.

---

Q: Does Erectol cause dependence or addiction?

Regulatory documents do not list physical dependence or addiction as a known adverse event based on clinical trials. However, some external research has discussed a possible risk of psychological dependence when the medicine is used in non-indicated circumstances.

---

Q: Is Erectol a drug that is reviewed often by regulatory agencies?

The drug is subject to periodic regulatory review, a process which involves the submission of safety and monitoring information.

---

Q: Is there a known effect of Erectol on fertility or sperm count?

Studies examined the active ingredient's effect on sperm motility and morphology in healthy volunteers. Official product information reports that these studies showed no significant differences in these factors when compared to placebo.

---

Q: Are there official registry studies following people who use Erectol?

Regulatory agencies may request or receive data from Post Marketing Commitment (PMC) studies and registries. These programs are designed to continuously monitor the use and safety profile of the drug following its approval.

Storage and Disposal of Erectol (Sildenafil Tablets)

Requirement	Official Regulatory Statement
Storage Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C (86 F).
Protection	Keep the tablets dry, away from excessive moisture, heat, and direct light. Keep the container tightly closed [1.4].
Child Safety	Keep out of the reach of children and pets [1.4], [3.1].
Disposal	Preferred Method: Use a drug take-back program or mail-back envelope [2.2], [2.7]. Prohibited Method: Do not flush down the toilet or pour into a drain [2.7].

Disposal for unused or expired tablets should prioritize drug take-back options. If no take-back program is available, the product must be removed from its container, mixed with an unappealing substance (like dirt or coffee grounds), sealed in a bag or container, and placed in the household trash [2.2], [2.7]. All personal information on the original packaging must be concealed or scratched out before disposal [2.8].